Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$152.78 ▼ -20.67
(-11.92%)
MKT CAP: $10.13B • VOL: 3.40M
52W L $23 52W H $220
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$128
MEDIAN
$171
MEAN
$174
HIGH
$208
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE TWST TAPE
TWST // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $184.86 | $175.70 | 2025-02-14 | $139.03 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $192.50 | $180.28 | 2025-02-06 | $143.61 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $174.17 | $168.06 | 2025-01-29 | $146.67 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $155.84 | — | 2025-01-17 | $149.72 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $134.45 | $145.14 | 2025-01-09 | $135.97 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $181.81 | $158.89 | 2024-12-18 | $132.92 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $148.20 | $154.31 | 2024-12-04 | $142.09 | -4.3% | 48% | C |